Myosin Va (myoV) and myosin VI (myoVI) are processive molecular motors that transport cargo in opposite directions on actin tracks. Because these motors may bind to the same cargo in vivo, we developed an in vitro "tug of war" to characterize the stepping dynamics of single quantum-dot-labeled myoV and myoVI motors linked to a common cargo. MyoV dominates its myoVI partner 79% of the time. Regardless of which motor wins, its stepping rate slows due to the resistive load of the losing motor (myoV, 2.1 pN; myoVI, 1.4 pN). Interestingly, the losing motor steps backward in synchrony with the winning motor. With ADP present, myoVI acts as an anchor to prevent myoV from stepping forward. This model system emphasizes the physical communication between opposing motors bound to a common cargo and highlights the potential for modulating this interaction by changes in the cell's ionic milieu.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161522 | PMC |
| http://dx.doi.org/10.1073/pnas.1104298108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Clin Lymphoma Myeloma Leuk
December 2024
Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment.
Mol Biol Rep
December 2024
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Colorectal cancer (CRC) ranks as the third most common cancer worldwide and remains a major cause of cancer-related deaths, necessitating the development of innovative therapeutic approaches beyond conventional treatment modalities. Conventional therapies, such as radiation, chemotherapy, and surgery, are hindered by challenges like imprecise targeting, substantial toxicity, and the development of resistance. Exosome-driven nano-immunotherapy has emerged as a groundbreaking approach that leverages the natural properties of exosomes-cell-derived vesicles known for their role in intercellular communication-to deliver therapeutic agents with high precision and specificity.
View Article and Find Full Text PDFDirect imaging with multidimensional labelling and high-content analysis allows quantitative categorization and characterizations of individual small extracellular vesicles and nanoparticles (sEVPs).
J Extracell Vesicles
December 2024
Institute for Digital Molecular Analytics and Science, Nanyang Technological University, Singapore, Singapore.
Article Synopsis
- * The study introduces a method using fluorescent labeling and advanced imaging techniques to categorize sEVPs from the same cell type into seven distinct subpopulations, revealing differences in composition and features.
- * Findings suggest that this new characterization approach can help differentiate sEVPs from cancerous and normal cells, potentially improving diagnostic and therapeutic strategies related to these vesicles.
Advances in nanotechnology-based approaches for the treatment of head and neck squamous cell carcinoma.
RSC Adv
December 2024
State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University Chengdu Sichuan 610041 China.
Article Synopsis
- - Head and neck squamous cell carcinoma (HNSCC) is a prevalent and aggressive cancer with high mortality rates, primarily due to traditional treatments like surgery, chemotherapy, and radiotherapy leading to poor survival outcomes and complications.
- - Innovative therapies such as immunotherapy, photodynamic therapy, and photothermal therapy are limited by ineffective targeting and results, while early detection methods are hindered by various challenges.
- - The rise of nanotechnology offers promising new strategies for HNSCC treatment through the use of nanoparticles (NPs), which can enhance drug delivery and targeting to tumors, showcasing unique advantages and highlighting the need for further research to overcome existing clinical hurdles.
The prospective roles of exosomes in pituitary tumors.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Pituitary neuroendocrine tumors are common, typically benign intracranial neoplasms arising from well-differentiated anterior pituitary cells with prevalence of clinically relevant pituitary tumor of 89 in 100 000 people. Despite the growing number of published studies, there is still a need for diagnostic and predictive biomarkers of pituitary adenomas. Prompt determination of tendency of the tumor for invasive growth and aggressive behavior would allow for earlier and more effective treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!